Merck Stock Gets Boost from Wolfe Research Price Target Hike

Merck & Co Inc's stock price has been boosted by Wolfe Research's positive rating update, which maintained its 'Outperform' rating and increased the price target from $155 to $180. This represents a percentage increase of 16.13%. The GF Value for Merck is calculated at $119.94, indicating that the stock is currently trading at a 28.7% premium compared to its intrinsic value.

The company's solid overall performance is reflected in its GF Score , which stands at 70/100. This score indicates strengths in profitability and growth, but weaknesses in momentum. Merck operates within the healthcare sector, primarily focusing on drug manufacturing with a market capitalization of approximately $380.78 billion.

Analysts generally maintain a positive outlook for Merck, with Wolfe Research's upgrade following similar moves from Goldman Sachs and UBS. However, caution is advised due to the stock's overvaluation and low momentum rank, suggesting that potential investors may want to wait for a more favorable entry point.